YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)

Botox


AddThis Social Bookmark Button

Health Canada Safety Information Regarding Botox

Botox, Myobloc Linked to Serious Side Effects, Deaths

In February 2008, the Food & Drug Administration (FDA) announced that Botox, Botox Cosmetic and Myobloc would undergo a safety review following reports of serious side effects, including the deaths of some children.  Botox, Botox Cosmetic and Myobloc are injectable drugs that contain botulinum toxin.  According to the FDA, most of the severe reactions occurred in children treated for limb spasticity associated with cerebral palsy, an off-label use of the drugs. 

Botox, which is made with botulinum toxin type A, is approved for treatment of conditions such as blepharospasm (spasm of the eyelids), cervical dystonia (severe neck muscle spasms), and severe primary axillary hyperhydrosis (excess sweating).  Botox Cosmetic, which also uses botulinum toxin Type A, is approved for temporary improvement in the appearance of moderate to severe facial frown lines. Myobloc, which is made from botulinum toxin Type B, is approved for the treatment of adults with cervical dystonia.

Botox, Botox Cosmetic, and Myobloc Side Effect Reports

In January 2008, the consumer advocacy group Public Citizen petitioned the agency two weeks ago to strengthen warnings on the products' labels because of serious adverse reactions. An analysis conducted by Public Citizen of FDA data found that between Nov. 1, 1997, and Dec. 31, 2006, the makers Botox, Botox Cosmetic and Myobloc had reported 180 U.S. cases of people developing serious conditions after receiving injections. Those 180 cases included 16 deaths, four of which occurred in children.

According to the FDA the Botox, Botox Cosmetic and Myobloc reactions reported resemble botulism.   The reactions have occurred when botulinum toxin spreads beyond the site where it was injected. The most serious cases had outcomes that included hospitalization and death, and occurred mostly in children treated for cerebral palsy-associated limb spasticity. Use of botulinum toxins for treatment of limb spasticity (severe arm and leg muscle spasms) in children or adults is not an approved use in the U.S. The FDA said that the adverse reactions may be due to overdosing

The reports of adult botulism cases described symptoms including patients experiencing difficulty holding up their heads, dysphagia and ptosis.  Some reports described systemic effects that occurred distant from the site of injection and included weakness and numbness of the lower extremities.  Among the adult cases that were serious, including hospitalization, none required intubation or ventilatory support. No deaths were reported. 

Legal Help

If you or a loved one has been seriously injured as a result of Botox, Botox Cosmetic or Myobloc, you have valuable legal rights.  Please fill out our online form for a free case evaluation by a qualified drug side effects attorney.

 

Botox Lawsuit Claims 7-Year-Old Died From Treatments

Jan 28, 2010
A woman in California has sued Allergan, the maker of  Botox, alleging that the drug caused the death of her 7-year-old daughter in 2007. According to a lawsuit filed by the mother of Kristen Spears, her daughter began receiving Botox injections when she was six to calm spasms in her legs caused by severe cerebral palsy. Experts hired by Kristen’s mother say that the girl died because Botox weakened muscles that controlled her breathing and swallowing, leading to respiratory failure...

Botox Maker Sues to Have Off-Label Marketing Rules Lifted

Oct 2, 2009 | Parker Waichman Alonso LLP
Allergan Inc. is claiming that rules forbidding it from distributing information about the off-label use of Botox wrinkle treatment and other drugs are a violation of its First Amendment right to free speech.  According to The  Wall Street Journal, the drug maker has filed suit against the Food & Drug Administration (FDA) over the restrictions.Using a drug in a way that has not been approved by the FDA is known as off-label use.  As we've reported in the past, doctors are...

FDA Issues Revised Botulinum Toxin Warnings

Aug 4, 2009 | Parker Waichman Alonso LLP
The U.S. Food and Drug Administration (FDA) just announced an update to a previous safety alert on four botulinum toxin drug products, noting that all now contain boxed warnings on their labels and have developed Medication Guides for patients, which was directed by the agency in April 2009.The boxed warning cautions that botulinum toxin effects may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. Those symptoms include potentially...

FDA Decision on Botox for Movement Disorder Delayed

May 27, 2009 | Parker Waichman Alonso LLP
Federal regulators have decided to wait on approving Botox as a treatment for upper limb spasticity in stroke victims.  According to a Reuters report, the Food & Drug Administration (FDA) wants to review a bit more information before deciding to expand the approved use of Botox to include treatment of  the movement disorder.Allergan markets two Botox products.  Botox Cosmetic is made from botulinum toxin type A, and is approved for temporary improvement in the appearance of...

Botox Rival Dysport Approved by FDA

May 1, 2009 | Parker Waichman Alonso LLP
On the same day it announced a black box warning for Botox and similar drugs, the Food & Drug Administration (FDA) approved another botulinum toxin injection product for the U.S. market.  But as we have reported previously, Dysport has been the subject of safety concerns in Australia - specifically, that it may result in birth defects if used to treat expectant mothers.Like Botox and  Botox Cosmetic, Dysport is made from botulinum toxin type A. It was approved by the FDA yesterday...

More Botox News

Defective Drugs
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Name of drug:

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2010 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising